DEVELOPMENT AND CHARACTERIZATION OF SUSTAINED RELEASE METHOTREXATE LOADED CUBOSOMES FOR TOPICAL DELIVERY IN RHEUMATOID ARTHRITIS
Objective: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are essential part of the administration of Rheumatoid Arthritis (RA). Methotrexate (MTX) is effective for tumor necrosis factor alpha (TNF-a) biologic agents, indicated only in minority of patients suffering from severe RA. MTX remains the "anchor drug" in the treatment of RA. For delivery improvement, novel pharmaceutical drug delivery system i.e. MTX-Cubosomes were developed.
Methods: Poloxamer 407 and Glycerol monooleate (Monoelin, MO) used and the formulation were characterized as a sustained release drug delivery system for Methotrexate. Different ratios of Monolein, Poloxamer 407 and water were used to develop the different cubosomes using homogenization and emulsification method. Characterization of formulations for morphology was performed and also particle size distribution by Transmission Electron Microscopy (TEM).
Results: Formulation showed the internal cubic structures of the vesicles. The particle size of the formulations was found to be ranging from 53.21 to 185.32 nm, zeta potential of the formulations varied from-18.20-36.10 mV. The cubosomal formulation exhibited good entrapment efficiency along with high drug loading. Compatibility with the excipients was also established. An in vitro release study was done using Franz Diffusion cell indicated sustained release of the formulation at a rate of 1.25 %/h. Cubosomes proved to be reliable system for sustained transdermal drug delivery system.
Conclusion: Methotrexate cubosomes is a novel medication delivery framework and in this examination it has been developed and characterized. The formulations were found to be promising in terms of its characterization parameters like particle size, zeta potential, entrapment efficiency, loading capacity, release kinetics, and stability, suitable for topical delivery.
2. Cotran R, Kumar V, Collins T. Robbins pathologic basis of disease. 6th Ed. Philadelphia PA: WB Saunders Company; 1999.
3. Lineker S, Badley E, Charles C. Defining morning stiffness in rheumatoid arthritis. J Rheumatol 1999;26:1052-7.
4. Aida Turturro Brings RA. Awareness Campaign to Philadelphia. Market Wire; 2005.
5. Lozada CJ, Firestein GS. Management of osteoarthritis. Kelley's Textbook of Rheumatology. 8th ed. Vol. 2. Philadelphia: Saunders Elsevier; 2009. p. 1563-77.
6. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. Kelley?s Textbook of rheumatology. 7th ed. Philadelphia: WB Saunders; 2005. p. 996-1042.
7. Rothschild BM, Rothschild C, Helbling M. Unified theory of the origins of erosive arthritis: conditioning as a protective/directing mechanism. J Rheumatol 2003;30:2095–102.
8. Spector TD. Rheumatoid Arthritis. Rheum Dis Clin North Am 1990;16:513-37.
9. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 y. Ann Rheum Dis 2003;62:722–7.
10. Goldring SR. A 55 y old woman with rheumatoid arthritis. JAMA 2005;283:524–31.
11. Rothschild BM, Turner KR, Deluca MA. Symmetrical erosive peripheral polyarthritis in the late archaic period of Alabama. Science 1998;241:1498-501.
12. Silman AJ, Macgregor AJ, Whiting S. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993;32:903-7.
13. Lee KW, Nguyen TH, Hanley T, Boyd BJ. Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. Int J Pharm 2009;365:190–9.
14. Caffrey M. A lipid’s eye view of membrane protein crystallization in mesophases. Curr Opin Struct Biol 2000;10:486–97.
15. Pan X, Han K, Peng X. Nanostructured cubosomes as advanced drug delivery system. Curr Pharm Des 2013;19:6290–7.
16. SL Morgan, RA Oster, JY Lee, GS Alarcon, JE Baggott. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheumatism 2004;50:3104–11.
17. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004;270:119–25.
18. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20.
19. Morsi NM, Abdelbary GA, Ahmed MA. Silver sulfadiazine based cubosome hydrogels for topical treatment of burns: development and in vitro/in vivo characterization. Eur J Pharm Biopharm 2014;86:178–89.
20. Salah S, Mahmoud AA, Kamel AO. Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies. Drug Delivery 2017;24:1, 846-56.
21. O'dell JR, Leff R, Paulsen G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
22. Alice R Oliveira, Lilia B Caland, Edilene G Oliveira, Eryvaldo ST Egito, Matheus FF Pedrosa, Arnobio A Silva Junior. HPLC-DAD and UV-Vis spectrophotometric methods for methotrexate assay in different biodegradable microparticles. J Brazilian Chem Soc 2015;26:649-59.
23. Strom P, Anderson DM. The cubic phase region in the system didodecyldimethyl-ammonium bromide-water-styrene. Langmuir 1992;8:691-709.
24. Lynch ML, Kochvar KK, Burns JL, Laughlin RG. Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes). Langmuir 2000;16:3537-42.
25. Engstrom S, Larsson K, Lindman B. Controlled release bioact. Mater 1998;15:105-6.
26. Engstrom S, Lindahl L, Wallin R. A study of polar lipid drug systems undergoing a thermoreversible lamellar-to-cubic phase transition. Engblom J Int J Pharm 1992;86:137-45.
27. Boyle E, German JB. Monoglycerides in membrane systems. Crit Rev Food Sci Nutr 1996;36:785-805.
28. Drummond CJ, Fong C. Surfactant self-assembly objects as novel drug delivery vehicles. Curr Opin Colloid Interface Sci 2000;4:449-56.
29. Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17:811–29.
30. Cutolo M. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729–35.
31. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903–11.
32. Salama AH, Mahmoud AA, Kamel R. A novel method for preparing surface-modified fluocinolone acetonide loaded PLGA nanoparticles for ocular use: in vitro and in vivo evaluations. AAPS PharmSciTech 2016;17:1159–72.
33. Korsmeyer RW, Gurny R, Doelker E. Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci 1983;72:1189–91.
34. Sharma K, Hallan SS, Lal B. Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability. Artif Cells Nanomed Biotechnol 2016;44:1448–56.
35. Neupane YR, Srivastava M, Ahmad N. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. Int J Pharm 2014;477:601–12.
36. Soni K, Mujtaba A, Kohli K. Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: formulation design, characterization, ex vivo, and in vivo assessment. Int J Biol Macromol 2017;103:139–51.
37. Peng X, Wen X, Pan X, Wang R, Chen B, Wu C. Design and in vitro evaluation of capsaicin transdermal controlled release cubic phase gels. AAPS PharmSciTech 2010;11:1405–10.
38. Tanaka N, Imai K, Okimoto K. Development of novel sustainedrelease system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Controlled Release 2005;108:386–95.
39. Babu SAR, Karki SS. Anti inflammatory activity of various extracts of roots of calotropis procera against different inflammation models. Int J Pharm Pharm Sci 2011;3:191-4.
40. Rege A, Juvekar P, Juvekar A. In vitro antioxidant and anti-arthritic activities of shilajit. Int J Pharm Pharm Sci 2012;4:650-3.
41. Irfan M, Verma S, Ram A. Preparation and characterization of ibuprofen loaded transferosome as a novel carrier for transdermal drug delivery system. Asian J Pharm Clin Res 2012;5:162-5.
42. Gayathri CR, Samuel V, Felix JW, Nirmala P. Comparative analysis of efficacy and safety of diacerein versus sadenosyl methionine in the management of osteoarthritis of knee joint. Int J Curr Pharm Res 2017;9:46-51.
43. Sanjaymitra PVSS, Ganesh GNK. Dissolution and solubility enhancement strategies: current and novel. J Crit Rev 2018;5:1-10.
44. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf [Last accessed on 10 Dec 2019].
This work is licensed under a Creative Commons Attribution 4.0 International License.